DDInter1918 DDInter927
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis of cGMP in the smooth muscle cells of the corpus cavernosum. PDE5 inhibitors, such as vardenafil, inhibit the degradation of cGMP and allow increased blood flow into the penis, resulting in an erection.[A258303,L45563,L45568]. Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil. The FDA approved the use of v
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Vardenafil {u} (Compound) resembles {v} (Compound) Sildenafil
Vardenafil {u} (Compound) resembles {v} (Compound) Udenafil
Vardenafil {u} (Compound) binds {v} (Gene) CYP3A4
Vardenafil {u} (Compound) upregulates {v} (Gene) ABCC5
Vardenafil {u} (Compound) downregulates {v} (Gene) RNH1
Vardenafil {u} (Compound) causes {v} (Side Effect) Amnesia
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metronidazole
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palonosetron
Vardenafil {u} may lead to a major life threatening interaction when taken with {v} Hydroxychloroquine
Vardenafil {u} may lead to a major life threatening interaction when taken with {v} Cisapride
Vardenafil (Compound) resembles Sildenafil (Compound)
Vardenafil (Compound) resembles Udenafil (Compound)
Vardenafil (Compound) binds CYP3A4 (Gene)
Vardenafil (Compound) upregulates ABCC5 (Gene)
Vardenafil (Compound) downregulates RNH1 (Gene)
Vardenafil (Compound) causes Amnesia (Side Effect)
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron
Vardenafil may lead to a major life threatening interaction when taken with Hydroxychloroquine
Vardenafil may lead to a major life threatening interaction when taken with Cisapride